John Furey, Imvax CEO
A neurosurgeon spent the past 30 years developing a neoantigen tumor vaccine. Now he has $112M for a pivotal test
As a neurosurgeon, David Andrews knew there wasn’t much he could do for his glioma patients after resecting — rarely fully — their tumor. Even with the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.